Clinical and radiological outcomes of ustekinumab in pediatric perianal Crohn’s disease: a multicenter retrospective study from the Pediatric IBD Porto Group of ESPGHAN
Inflammatory Bowel Diseases · 01.10.2026 · 32 (10) · 1871-1879
DOI: 10.1093/ibd/izag091 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 02.06.2026. Verfasst von Ido Orlin und 13 weiteren Autor:innen. Beteiligte Einrichtung: Leumit Health Services, Haifa, Israel. Hauptthemen laut MEDLINE: Anus Diseases, Crohn Disease, Ustekinumab. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Pediatric Research Foundation (Finland) and Helsinki University, Pediatric Research Foundation, Helsinki University.
Abstract (Originalsprache)
Background
Perianal Crohn’s disease (pCD) is a severe pediatric phenotype with high morbidity. Although antitumor necrosis factor (TNF) agents are first-line therapy, remission is not achieved in a subset of patients. We aimed to evaluate clinical and radiological outcomes of ustekinumab (UST) in pediatric patients with pCD.
Methods
This is a multicenter retrospective study including pediatric patients with pCD treated with UST between 2016 and 2023. Primary outcomes were clinical and radiological remission at predefined time points. Clinical remission was defined as absence of fistula drainage without antibiotics or unplanned perianal interventions. Radiological remission was defined as a Pediatric MRI-Based perianal Crohn’s Disease (PEMPAC) score of <10 on pelvic MRI.
Results
Fifty patients were included, of whom 2 were anti-TNF-naive. The median age at UST initiation was 15 years (IQR 12.4-16.2). Clinical remission was observed in 46% (23/50; P = .006 vs baseline), 48% (23/48; P = .036 vs baseline), and 42% (19/45; P = .13 vs baseline) at weeks 26, 52, and 104, respectively. Radiological remission was 29% (10/34) and 30% (13/43) at weeks 52 and 104, respectively (both P < .01 vs baseline). In multivariable analysis, higher baseline PEMPAC scores were independently associated with lower odds of both clinical (P < .01; OR 0.88, 95% CI 0.68-0.95) and radiological remission (P < .01; OR 0.81, 95% CI 0.62-0.94).
Conclusions
UST was associated with perianal clinical remission in a substantial proportion of pediatric patients, approaching 50% at 1 year, and radiological healing in about one-third at 2 years, supporting its potential role in pediatric pCD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Leumit Health Services, Haifa, Israel.
- Pediatric Department, Emek Medical Center, Afula, Israel.
- School of Medicine, Norfolk and Norwich University Hospital, Jenny Lind Children's Hospital, Pediatric Gastroenterology, University of East Anglia (UEA), Norwich, United Kingdom.
- Pediatric Gastroenterology Institute, Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, The Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Department of Paediatric Vittore Buzzi Children's Hospital and Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.
- Division of Pediatric Gastroenterology, Hepatology and Nutrition, Children's Hospital, Inselspital, University of Bern, Bern, Switzerland.
ORCID-Profile: Lorenzo Norsa, Christiane Sokollik, Kaija-Leena Kolho, Anne Griffiths, Firas Rinawi
Förderung
- Pediatric Research Foundation (Finland) and Helsinki University
- Pediatric Research Foundation
- Helsinki University
Zitieren
APA
Orlin, I., Younis, B., Gasparetto, M., Yerushalmy-Feler, A., Norsa, L., Sokollik, C., Rohani, P., Zárubová, K., D'Arcangelo, G., Pochesci, S., Lozano-Ruf, A., Kolho, K. L., Griffiths, A., & Rinawi, F. (2026). Clinical and radiological outcomes of ustekinumab in pediatric perianal Crohn’s disease: a multicenter retrospective study from the Pediatric IBD Porto Group of ESPGHAN. Inflammatory Bowel Diseases, 32(10), 1871-1879. https://doi.org/10.1093/ibd/izag091
Vancouver
Orlin I, Younis B, Gasparetto M, Yerushalmy-Feler A, Norsa L, Sokollik C, et al. Clinical and radiological outcomes of ustekinumab in pediatric perianal Crohn’s disease: a multicenter retrospective study from the Pediatric IBD Porto Group of ESPGHAN. Inflammatory Bowel Diseases. 2026;32(10):1871-1879. doi:10.1093/ibd/izag091
BibTeX
@article{Orlin2026,
author = {Orlin, Ido and Younis, Balsam and Gasparetto, Marco and Yerushalmy-Feler, Anat and Norsa, Lorenzo and Sokollik, Christiane and Rohani, Pejman and Zárubová, Kristýna and D'Arcangelo, Giulia and Pochesci, Saverio and Lozano-Ruf, Ana and Kolho, Kaija-Leena and Griffiths, Anne and Rinawi, Firas},
title = {Clinical and radiological outcomes of ustekinumab in pediatric perianal Crohn’s disease: a multicenter retrospective study from the Pediatric IBD Porto Group of ESPGHAN},
journal = {Inflammatory Bowel Diseases},
year = {2026},
volume = {32},
number = {10},
pages = {1871--1879},
doi = {10.1093/ibd/izag091}
}
EUVIMED